Paradoxical labeling of radiosurgically treated quiescent tumors with Ki67, a marker of cellular proliferation

被引:5
|
作者
Jennelle, R
Gladson, C
Palmer, C
Guthrie, B
Markert, J
机构
[1] Carraway Methodist Med Ctr, Dept Radiat Oncol, Birmingham, AL 35234 USA
[2] Univ Alabama, Dept Pathol, Div Neuropathol, Birmingham, AL 35294 USA
[3] Univ Alabama, Dept Surg, Div Neurosurg, Birmingham, AL 35294 USA
关键词
Ki67; MIB; cellular proliferation; stereotactic radiosurgery; adverse radiation effect; radionecrosis; complications;
D O I
10.1159/000056438
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Ki67 (also known as MIB) is a monoclonal antibody staining agent, which is routinely used as a marker of cellular proliferation. It is used to evaluate the proliferative potential of malignant tumors, since it is thought to stain only those cells undergoing active division. The paradoxical elevation of the Ki67 labeling index observed in radiosurgically treated benign and malignant tumors is reported. Ten patients, who had previously undergone either linac or Gamma Knife radiosurgery, underwent surgical resection for a radiographically quiescent tumor. One patient underwent autopsy after dying from complications of radiosurgery. All were thought to be suffering from adverse radiation effect (ARE) and were refractory to conservative management. None were thought to have a recurrent tumor. All of the resected tumors were subjected to analysis with Ki67 staining. Despite the radiographic stability of the tumors, all manifested significantly elevated populations of cells exhibiting positivity for Ki67 antigen. This staining pattern would suggest a significant proliferative potential, which did not match the observed clinical course. The literature is reviewed and possible mechanisms to explain the paradoxical findings are presented. Copyright (C) 1999 S. Karger AG. Basel.
引用
收藏
页码:45 / 52
页数:8
相关论文
共 50 条
  • [21] Association of ki67 Index with Recurrence in Gastrointestinal Stromal Tumors
    Segales-Rojas P.
    Lino-Silva L.S.
    Aguilar-Cruz E.
    Salcedo-Hernández R.A.
    Journal of Gastrointestinal Cancer, 2018, 49 (4) : 543 - 547
  • [22] Assessment of the Ki67 labeling index: a Japanese validation ring study
    Niikura, Naoki
    Sakatani, Takashi
    Arima, Nobuyuki
    Ohi, Yasuyo
    Honma, Naoko
    Kanomata, Naoki
    Yoshida, Kazuya
    Kadoya, Takayuki
    Tamaki, Kentaro
    Kumaki, Nobue
    Iwamoto, Takayuki
    Sugie, Tomoharu
    Moriya, Takuya
    BREAST CANCER, 2016, 23 (01) : 92 - 100
  • [23] Ki67 Proliferative Index in Carcinoid Tumors Involving Ovary
    Xiaotun Zhang
    Andrea Jones
    Sarah M. Jenkins
    Yajue Huang
    Endocrine Pathology, 2018, 29 : 43 - 48
  • [24] Ki67 Proliferative Index in Carcinoid Tumors Involving Ovary
    Zhang, Xiaotun
    Jones, Andrea
    Jenkins, Sarah M.
    Huang, Yajue
    ENDOCRINE PATHOLOGY, 2018, 29 (01) : 43 - 48
  • [25] Ki67, gelsolin and PTEN expression in sarcomatoid renal tumors
    Visapää, H
    Seligson, D
    Huang, Y
    Rao, JY
    Belldegrun, A
    Horvath, S
    Palotie, A
    UROLOGICAL RESEARCH, 2003, 30 (06): : 387 - 389
  • [26] Ki-67 protein as a tumour proliferation marker
    Menon, Sunil Sankunny
    Guruvayoorappan, Chandrasekharan
    Sakthivel, Kunnathur Murugesan
    Rasmi, Rajan Radha
    CLINICA CHIMICA ACTA, 2019, 491 : 39 - 45
  • [27] Ki-67: more than a proliferation marker
    Xiaoming Sun
    Paul D. Kaufman
    Chromosoma, 2018, 127 : 175 - 186
  • [28] Ki-67: more than a proliferation marker
    Sun, Xiaoming
    Kaufman, Paul D.
    CHROMOSOMA, 2018, 127 (02) : 175 - 186
  • [29] Immunohistochemical assessment of Ki-67 as prognostic cellular proliferation marker in anal canal carcinoma
    Indinnimeo, M
    Cicchini, C
    Stazi, A
    Limiti, MR
    Ghini, C
    Mingazzini, P
    Vecchione, A
    JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2000, 19 (04) : 471 - 475
  • [30] Intratumoral heterogeneity affects tumor regression and Ki67 proliferation index in perioperatively treated gastric carcinoma
    Brink, Magnus Kock Am
    Dunst, Laura Sophie
    Behrens, Hans-Michael
    Krueger, Sandra
    Becker, Thomas
    Roecken, Christoph
    BRITISH JOURNAL OF CANCER, 2023, 128 (02) : 375 - 386